Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diffuse Large B Cell Lymphoma (DLBCL): early-phase trial registry
5 of 11 indexed Diffuse Large B Cell Lymphoma (DLBCL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 5 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Diffuse Large B Cell Lymphoma (DLBCL): 11 US clinical trials tracked, 5 recruiting.
Diffuse Large B Cell Lymphoma (DLBCL) is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition diffuse-large-b-cell-lymphoma-dlbcl
OPEN 5 | RECR 45% | LATE 2 | EARLY 8 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Breast Carcinoma (45% recruiting · 11 trials)
Diffuse Large B Cell Lymphoma (DLBCL) lists 5 open slots (45% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diffuse Large B Cell Lymphoma (DLBCL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diffuse Large B Cell Lymphoma (DLBCL) recruits in line with its size-band peers.
5 of 11 indexed trials (45.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Diffuse Large B Cell Lymphoma (DLBCL) research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Diffuse Large B Cell Lymphoma (DLBCL) enrolment sits around 115 participants.
Median target enrolment is 115 among the 11 trials that report a genuine target (sentinel values excluded). 5 of those (45.5%) plan for fewer than 100 participants.
-
Diffuse Large B Cell Lymphoma (DLBCL) research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT05131022
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma
NCT07188558
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics
NCT04830137
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Cancer Center
NCT06765317
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Danielle Wallace
NCT06828991
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals
NCT06091865
Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
Memorial Sloan Kettering Cancer Center
NCT01829958
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center
NCT02570542
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Patrick C. Johnson, MD
NCT05583149
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
Novartis Pharmaceuticals
NCT02445248
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT04450069
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Diffuse Large B Cell Lymphoma (DLBCL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diffuse Large B Cell Lymphoma (DLBCL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diffuse Large B Cell Lymphoma (DLBCL) page
11 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Diffuse Large B Cell Lymphoma (DLBCL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Diffuse Large B Cell Lymphoma (DLBCL) trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diffuse Large B Cell Lymphoma (DLBCL) condition card totals 11 registered trials; most-linked intervention Lymphodepleting chemotherapy; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.